During the forecast period 2023 to 2033, the Postoperative Nausea And Vomiting (PONV) Management Market is expected to grow at a value of 12.8% CAGR, according to Future Market Insights. By the year 2033, the global market for Postoperative nausea and vomiting (PONV) management is expected to rise up to a market valuation of US$ 3.9 Billion. Growth of the market can be attributed to various factors, including the increasing number of surgical procedures being performed worldwide, the rising prevalence of PONV, and the development of novel antiemetic drugs and treatment methods.

North America and Europe are currently the largest markets for PONV management, primarily due to the high prevalence of PONV in these regions and the availability of advanced healthcare facilities. However, the Asia-Pacific region is expected to experience the highest growth rate in the coming years, due to the increasing number of surgical procedures being performed in countries like China and India, as well as the growing demand for effective PONV management options in the region.

Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16883

Various companies are working towards developing new and effective drugs for PONV management, including Acacia Pharma, Eisai Co., Ltd., GlaxoSmithKline, Hoffmann-La Roche AG, and Merck & Co., Inc. These companies are also focusing on strategic collaborations and partnerships to expand their market presence and offer better treatment options to patients.

Key Takeaways from the Market Study

• The global Postoperative nausea and vomiting (PONV) management market is expected to grow with a 12.8% CAGR during 2023 to 2033.
• By distribution channel, hospital pharmacies are expected to hold 49% of the market share in 2023 for Postoperative nausea and vomiting (PONV) management market.
• North America is expected to possess 47% market share for Postoperative nausea and vomiting (PONV) management market in 2023.
• Europe Postoperative nausea and vomiting (PONV) management market size is expected to possess 43% market share in 2023.

“The PONV management market is expected to experience significant growth in the coming years, driven by increasing demand for effective treatment options and advancements in drug development.” states an FMI analyst

Competitive Landscape

Key players in the postoperative nausea and vomiting (PONV) management market are Acacia Pharma, Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc, Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, Merck and Co., GlaxoSmithKline Corporation

• Acacia Pharma has developed a patient-controlled analgesia (PCA) system for PONV management. The PCA system delivers a combination of opioids and antiemetic medications through a patient-controlled pump. The system has been shown to be highly effective in reducing the incidence of PONV and improving patient satisfaction.
• Roche's key antiemetic medications for PONV management is Kytril (granisetron). Kytril is a selective 5-HT3 receptor antagonist that works by blocking the action of serotonin, a neurotransmitter that is involved in the development of nausea and vomiting. The drug is administered intravenously and has been shown to be highly effective in the prevention and treatment of PONV.

Key Segments Profiled in the Postoperative Nausea and Vomiting (PONV) Management Industry Survey

Treatment Type:

• Serotonin Antagonists
• Steroids
• Dopamine Antagonists
• Neurokinin NK-1 Receptor Antagonists
• Non-pharmacological Treatment

Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies and Drug Stores

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa